Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clobetasol Propionate

FDA-approved product (cream, topical), marketed as Byqlovi, Clobetasol Propionate, Clobetasol Propionate (Emollient) and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clobetasol Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, very potent (group iv)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clobetasol Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clobetasol Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy

    NCT01407471 · start 2011-09

    Registered record
    Registry ID
    NCT01407471
    Conditions
    Cutaneous Atrophy Due to Corticosteroids
    Interventions
    Clobetasol + Spironolactone; Clobetasol + Placebo; Placebo + Spironolactone; Placebo + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Atrophy Due to Corticosteroids
    InterventionClobetasol + Spironolactone; Clobetasol + Placebo; Placebo + Spironolactone; Placebo + Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study Assessing GW870086's Potential to Cause Skin Thinning

    NCT01381445 · start 2011-04-14

    Registered record
    Registry ID
    NCT01381445
    Conditions
    Dermatitis, Atopic
    Interventions
    GW870086 0.2%; GW870086 2%; Clobetasol Propionate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04-14
    Completion
    2011-07-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionGW870086 0.2%; GW870086 2%; Clobetasol Propionate; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails

    NCT01703325 · start 2010-11

    Registered record
    Registry ID
    NCT01703325
    Conditions
    Psoriatic Nails
    Interventions
    0.1% triamcinolone , 0.05% clobetasol propionate ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-11
    Completion
    2012-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriatic Nails
    Intervention0.1% triamcinolone , 0.05% clobetasol propionate ointment
    PhasePhase 4
    Registry statusCompleted

  • Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

    NCT01235442 · start 2010-09

    Registered record
    Registry ID
    NCT01235442
    Conditions
    Psoriasis
    Interventions
    1=Etanercept; 2=Clobetasol propionate foam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-12
    Enrolment
    592

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Intervention1=Etanercept; 2=Clobetasol propionate foam
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

    NCT01012713 · start 2010-06

    Registered record
    Registry ID
    NCT01012713
    Conditions
    Chronic Stable Plaque Psoriasis
    Interventions
    Clobex Spray; Vectical Ointment; Excimer Laser
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    2014-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Stable Plaque Psoriasis
    InterventionClobex Spray; Vectical Ointment; Excimer Laser
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

    NCT01205880 · start 2009-12

    Registered record
    Registry ID
    NCT01205880
    Conditions
    Psoriasis
    Interventions
    Calcitriol ointment; Clobetasol spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-12
    Completion
    2010-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionCalcitriol ointment; Clobetasol spray
    PhasePhase 4
    Registry statusCompleted

  • Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

    NCT00988637 · start 2009-10

    Registered record
    Registry ID
    NCT00988637
    Conditions
    Plaque Psoriasis
    Interventions
    Vectical™ Ointment weekdays and Clobex® Spray weekends regimen; Clobex® Spray morning and Vectical™ Ointment evening regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-03
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionVectical™ Ointment weekdays and Clobex® Spray weekends regimen; Clobex® Spray morning and Vectical™ Ointment evening regimen
    PhasePhase 4
    Registry statusCompleted

  • Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

    NCT00881868 · start 2009-04

    Registered record
    Registry ID
    NCT00881868
    Conditions
    Scalp Psoriasis
    Interventions
    clobetasol propionate spray 0.05%; Vehicle spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-12
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScalp Psoriasis
    Interventionclobetasol propionate spray 0.05%; Vehicle spray
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

    NCT00852761 · start 2009-03

    Registered record
    Registry ID
    NCT00852761
    Conditions
    Plaque-Type Psoriasis
    Interventions
    Olux-E Foam; Clobex lotion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque-Type Psoriasis
    InterventionOlux-E Foam; Clobex lotion
    PhasePhase 4
    Registry statusCompleted

  • Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

    NCT00862654 · start 2009-03

    Registered record
    Registry ID
    NCT00862654
    Conditions
    Scalp Seborrheic Dermatitis
    Interventions
    clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week); clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week); clobetasol propionate shampoo (2/week); ketoconazole shampoo (2/week)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScalp Seborrheic Dermatitis
    Interventionclobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week); clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week); clobetasol propionate shampoo (2/week); ketoconazole shampoo (2/week)
    PhasePhase 3
    Registry statusCompleted

  • Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

    NCT00658788 · start 2008-03

    Registered record
    Registry ID
    NCT00658788
    Conditions
    Psoriasis
    Interventions
    clobetasol propionate spray 0.05%; calcitriol ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-01
    Enrolment
    305

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Interventionclobetasol propionate spray 0.05%; calcitriol ointment
    PhasePhase 3
    Registry statusCompleted

  • Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid

    NCT02313870 · start 2008-01-22

    Registered record
    Registry ID
    NCT02313870
    Conditions
    Bullous Pemphigoid
    Interventions
    clobetasol propionate + Methotrexate; clobetasol propionate alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01-22
    Completion
    2015-12-31
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBullous Pemphigoid
    Interventionclobetasol propionate + Methotrexate; clobetasol propionate alone
    PhasePhase 3
    Registry statusCompleted

  • Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

    NCT00470392 · start 2007-05

    Registered record
    Registry ID
    NCT00470392
    Conditions
    Psoriasis
    Interventions
    Imiquimod; Clobetasol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2007-05
    Completion
    2012-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionImiquimod; Clobetasol
    PhaseNot applicable
    Registry statusTerminated

  • Subject Preference for Scalp Psoriasis Treatment

    NCT00438399 · start 2007-02

    Registered record
    Registry ID
    NCT00438399
    Conditions
    Scalp Psoriasis
    Interventions
    C. propionate - Corticosteroid 1; C. propionate- Corticosteroid 2; C. propionate -Corticosteroid 3; Corticosteroid 1- C. propionate; Corticosteroid 2 - C. propionate; Corticosteroid 3 - C. propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-02
    Completion
    2008-02
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScalp Psoriasis
    InterventionC. propionate - Corticosteroid 1; C. propionate- Corticosteroid 2; C. propionate -Corticosteroid 3; Corticosteroid 1- C. propionate +2 more
    PhasePhase 3
    Registry statusCompleted

  • Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

    NCT00393263 · start 2006-10

    Registered record
    Registry ID
    NCT00393263
    Conditions
    Lichen Sclerosus
    Interventions
    pimecrolimus and clobetasol; clobetasol 0.05% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-10
    Completion
    2009-10
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Sclerosus
    Interventionpimecrolimus and clobetasol; clobetasol 0.05% cream
    PhasePhase 2
    Registry statusCompleted